The Pharmaceutical Journal Vol 264 No 7102p970
June 24, 2000 Products
Glaxo Wellcome has received approval from the Medicines Control Agency to market Seretide (fluticasone propionate plus salmeterol xinafoate) in a metered dose inhaler delivery device. Seretide Evohaler is CFC-free and will be available in the following three strengths: Seretide 50 (salmeterol [as xinafoate] 25µg, fluticasone propionate 50µg), Seretide 125 (salmeterol [as xinafoate] 25µg, fluticasone propionate 125µg) and Seretide 250 (salmeterol [as xinafoate] 25µg, fluticasone propionate 250µg). Seretide Evohaler is licensed for adults and adolescents aged 12 years and over. Each metered dose inhaler will contain 120 doses. The company says that the product should be available by the end of July. Prices to be confirmed.
Citation: The Pharmaceutical Journal URI: 20001994
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com